NewsBenzingaAgenus präsentiert Forschung zu Botensilimab, einem Fc-verstärkten multifunktionalen Anti-CTLA-4-Antikörper, in Kombination mit Balstilimab, einem Anti-PD-1-Antikörper, auf der SITC 2026 Agenus präsentiert Forschung zu Botensilimab, einem Fc-verstärkten multifunktionalen Anti-CTLA-4-Antikörper, in Kombination mit Balstilimab, einem Anti-PD-1-Antikörper, auf der SITC 2026 Benzinga 2026.10.02 13:03 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Overweight on First Solar, Lowers Price Target to $252 Karooooo Q2 Adj. EPS $0.57, Inline, Sales $100.292M Beat $97.720M Estimate Karooooo Affirms FY2027 GAAP EPS Guidance of $2.35-$2.44 vs $2.41 Est Lear Appoints Jared Fedele CFO, Effective March 1, 2027, Succeeding Jason Cardew Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures 'Activist Starboard Prepares To Nominate Directors At Knife River; Starboard Is Pushing Knife River To Improve Margins Or Consider A Sale, Sources Say' - Reuters News
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
'Activist Starboard Prepares To Nominate Directors At Knife River; Starboard Is Pushing Knife River To Improve Margins Or Consider A Sale, Sources Say' - Reuters News
